Medline (NASDAQ:MDLN) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of Medline (NASDAQ:MDLN) in a research report released on Monday morning, Marketbeat reports. The firm issued a buy rating and a $46.00 target price on the stock.

Several other research analysts also recently issued reports on MDLN. Deutsche Bank Aktiengesellschaft assumed coverage on Medline in a report on Monday. They set a “hold” rating and a $40.00 price objective on the stock. BMO Capital Markets started coverage on Medline in a research report on Monday. They set an “outperform” rating and a $45.00 target price for the company. Robert W. Baird assumed coverage on Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price target on the stock. Piper Sandler started coverage on Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Finally, Morgan Stanley began coverage on Medline in a report on Sunday. They set an “overweight” rating and a $48.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Up 1.3%

Shares of MDLN stock opened at $43.41 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Transactions at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider directly owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. This represents a 55.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Charles N. Mills purchased 2,579,310 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the transaction, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.